$2.1 Billion is the total value of Redmile Group, LLC's 68 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 28.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMGN | Sell | IMMUNOGEN INC | $277,779,228 | -17.0% | 17,503,417 | -1.3% | 13.22% | +2.9% |
| KRYS | Sell | KRYSTAL BIOTECH INC | $232,390,572 | -22.9% | 2,003,367 | -21.9% | 11.06% | -4.4% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $206,046,591 | -16.2% | 16,944,621 | -13.4% | 9.80% | +3.9% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $89,510,617 | +5.8% | 1,769,684 | -2.3% | 4.26% | +31.2% |
| REPL | Sell | REPLIMUNE GROUP INC | $71,244,705 | -30.6% | 4,163,922 | -5.8% | 3.39% | -14.0% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $56,926,884 | -17.1% | 4,475,384 | -8.3% | 2.71% | +2.8% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $45,021,014 | -21.8% | 1,635,938 | -3.5% | 2.14% | -3.0% |
| IMVT | Sell | IMMUNOVANT INC | $42,325,512 | +16.1% | 1,102,514 | -42.6% | 2.01% | +44.0% |
| CTLT | Sell | CATALENT INC | $39,791,672 | -21.0% | 873,966 | -24.8% | 1.89% | -2.1% |
| BEAM | Sell | BEAM THERAPEUTICS INC | $35,346,886 | -25.5% | 1,469,725 | -1.0% | 1.68% | -7.6% |
| Sell | VENTYX BIOSCIENCES INC | $32,295,427 | +4.7% | 929,900 | -1.1% | 1.54% | +29.8% | |
| RPTX | Sell | REPARE THERAPEUTICS INC | $29,048,716 | +13.1% | 2,404,695 | -1.0% | 1.38% | +40.2% |
| DXCM | Sell | DEXCOM INC | $22,801,680 | -38.6% | 244,391 | -15.5% | 1.08% | -23.9% |
| NRIX | Sell | NURIX THERAPEUTICS INC | $22,391,780 | -21.6% | 2,848,827 | -0.3% | 1.06% | -2.8% |
| Sell | ENTRADA THERAPEUTICS INC | $20,287,200 | +2.2% | 1,284,000 | -2.1% | 0.96% | +26.6% | |
| STOK | Sell | STOKE THERAPEUTICS INC | $15,258,422 | -63.7% | 3,872,696 | -2.1% | 0.73% | -55.0% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $14,332,443 | -66.8% | 419,568 | -62.6% | 0.68% | -58.8% |
| CRL | Sell | CHARLES RIV LABS INTL INC | $13,009,544 | -45.9% | 66,382 | -41.9% | 0.62% | -32.9% |
| VERV | Sell | VERVE THERAPEUTICS INC | $10,737,643 | -46.1% | 809,777 | -23.7% | 0.51% | -33.1% |
| STXS | Sell | STEREOTAXIS INC | $9,109,951 | -6.6% | 5,765,792 | -9.5% | 0.43% | +15.8% |
| RAPT | Sell | RAPT THERAPEUTICS INC | $7,104,884 | -12.0% | 427,490 | -1.0% | 0.34% | +9.0% |
| Sell | SOMALOGIC INC | $954,659 | -77.9% | 399,439 | -78.6% | 0.04% | -72.9% | |
| TKNO | Sell | ALPHA TEKNOVA INC | $793,934 | -3.7% | 284,564 | -7.9% | 0.04% | +18.8% |
| HOOK | Sell | HOOKIPA PHARMA INC | $655,282 | -77.4% | 1,063,769 | -67.7% | 0.03% | -72.1% |
| Sell | SONENDO INC | $306,071 | -54.8% | 410,393 | -17.6% | 0.02% | -42.3% | |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -2,912,228 | -100.0% | -0.09% | – |
| GRFS | Exit | GRIFOLS S Asp adr rep b nvt | $0 | – | -600,684 | -100.0% | -0.21% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -1,698,626 | -100.0% | -0.21% | – |
| Exit | STEVANATO GROUP S P A | $0 | – | -218,169 | -100.0% | -0.27% | – | |
| Exit | ACELYRIN INC | $0 | – | -364,493 | -100.0% | -0.29% | – | |
| MDVL | Exit | MEDAVAIL HOLDINGS INC | $0 | – | -34,604,516 | -100.0% | -0.33% | – |
| IQV | Exit | IQVIA HLDGS INC | $0 | – | -94,409 | -100.0% | -0.81% | – |
| ZBH | Exit | ZIMMER BIOMET HOLDINGS INC | $0 | – | -151,372 | -100.0% | -0.85% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLC | $0 | – | -341,882 | -100.0% | -1.63% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INC | $0 | – | -489,208 | -100.0% | -1.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
| 4 | 2024-03-05 |
| SC 13D/A | 2024-03-05 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.